Ikarian Capital’s Cabaletta Bio CABA Stock Holding History

Ikarian Capital’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.42M	Hold	900,000	–	–	0.2%	89
2025 Q4	$1.97M	Buy	+900,000	New	+$2.23M	0.15%	102
2024 Q1	–	Sell	-216,620	Closed	-$4.65M	–	146
2023 Q4	$4.92M	Buy	+216,620	New	+$3.64M	0.46%	59
2023 Q1	–	Sell	-30,286	Closed	-$280K	–	121
2022 Q4	$280K	Sell	30,286 -138,337	-82%	-$504K	0.07%	69
2022 Q3	$109K	Sell	168,623 -775,808	-82%	-$934K	0.02%	98
2022 Q2	$1M	Sell	944,431 -75,639	-7%	-$107K	0.18%	75
2022 Q1	$2.07M	Buy	1,020,070 +49,672	+5%	+$130K	0.27%	68
2021 Q4	$3.68M	Sell	970,398 -217,500	-18%	-$2.32M	0.55%	42
2021 Q3	$14.4M	Buy	1,187,898 +240,770	+25%	+$2.22M	1.02%	23
2021 Q2	$8.14M	Buy	947,128 +557,744	+143%	+$5.48M	0.66%	43
2021 Q1	$4.32M	Buy	+389,384	New	+$4.76M	0.15%	132

Other funds holding CABA

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ikarian Capital's CABA Position: Q1 2026 in Review

Ikarian Capital held its Cabaletta Bio (CABA) position steady in Q1 2026 at 900,000 shares worth $2.42M. The position accounts for 0.2% of the portfolio, ranked #89.

Ikarian Capital first reported a position in CABA in Q1 2021 and has held it in 11 quarters since. The position peaked at $14.4M in Q3 2021. 108 funds tracked by Wall St. Rank hold CABA as of Q1 2026.

Ikarian Capital held 900,000 shares of Cabaletta Bio worth $2.42M as of Q1 2026.
Ikarian Capital left its Cabaletta Bio share count unchanged in Q1 2026.
Cabaletta Bio made up 0.2% of Ikarian Capital's portfolio in Q1 2026, its #89 holding.
Ikarian Capital first reported a position in Cabaletta Bio in Q1 2021 and has held it in 11 quarters since.
Ikarian Capital's Cabaletta Bio position peaked at $14.4M in Q3 2021.
108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.